Kintu K, Malaba T, Nakibuka J, et al. RCT of Dolutegravir vs Efavirenz-based therapy initiated in late pregnancy: DOLPHIN-2. CROI 2019, abstract 40-LB.
Anti-C5a-antilichaam vilobelimab veilig bij ernstige COVID-19
feb 2021 | Pneumonie, Virale infecties